


## Immunodox®-Cyanur (PEGylated)

### DESCRIPTION

---

In order to develop a rapid and straightforward coupling procedure at the PEG terminus, a method of direct coupling antibodies to the PEG terminus of liposomes was introduced by Bendas *et al.* In this methodology, antibodies are simply attached to the PEG terminus of liposomes, which had been endgroup-functionalized with cyanuric chloride, in mild basic conditions (pH 8.8) without prior antibody derivatizations. It has been shown that in order to obtain a stable attachment of proteins on liposome, the DSPE-PEG-cyanur was added into the liposomes to chemically conjugate with proteins to form a stable complex and minimize the denaturation of proteins.


Proteins can be covalently coupled to the liposomes via amine-reactive cyanur-groups, either directly to the vesicle surface using cyanuric chloride-activated DSPE (cyanur-DSPE) or to the distal ends of PEG-spacers using activated cyanur-PEG-PE (ammonium salt). Cyanuric chloride at the PEG terminus functions to link peptides, antibodies and other amine-containing biomolecules or nanoparticles via a nucleophilic substitution reaction under basic conditions. Antibodies or other proteins can be conjugated without any previous derivatization.



Reaction between doxorubicin liposomes containing cyanur with N- terminus of antibody.

## FORMULATION INFORMATION

### Immunodox®-Cyanur (PEGylated)

Lipid Composition	Concentration (mg/ml)	Concentration (mM)	Molar Ratio Percentage
Hydrogenated Soy PC	9.58	12.22	57
Cholesterol	3.19	8.25	38
DSPE-PEG(2000)	2.5	0.89	4
DSPE-PEG(2000)-Cyanur	0.65	0.22	1
			
<b>Total</b>	<b>15.92 mg/ml</b>	<b>21.58 mM</b>	<b>100</b>

Buffer and Liposome Size	Specification
Buffer	Borate Buffer
pH	8.8
Liposome Size	100 nm
Encapsulated Doxorubicin	2 mg/ml (3.45 mM)

## CONJUGATION PROTOCOL

---

### Materials and Equipment

In order to conjugate the amine on your antibody, protein or peptide to Immunodox®-Cyanur (PEGylated) liposomes you will need:

1. [Float-A-Lyzer®](#) with a proper MWCO that easily allows the cleanup of your liposome conjugated ligand from free and non-conjugated protein/peptide/ligand. You need to make sure that the MWCO is below 1,000,000 dalton. At 1,000,000 dalton, the pore size on the dialysis membrane gets close to 100 nm and therefore your liposomes can be dialyzed out. You cannot use dialysis cassettes blindly. Please understand the technique before using either spin columns or dialysis cassettes. If you do not use the correct MWCO, you can lose your entire prep. In this case, we recommend using a dialysis cassette with MWCO of 300,000 dalton.
2. [Borate buffer](#). You can either make the borate buffer or purchase it from a chemical vendor. In any case, you need to make sure that the pH is adjusted to 8.8.

### Preparation Method

1. The total lipid concentration in Immunodox®-Cyanur is 21.58 mM. 1% mol of the lipid in liposomes contains PEG-Cyanur group and only half of them are exposed to the outside of the liposomes, which is equal to 0.11 mM of reactive conjugable lipid. For 2 ml volume liposome, this is equal to  $2.2 \times 10^{-7}$  mol, and for 5 ml volume liposome, this is equal to  $5.5 \times 10^{-7}$  mol of PEG-Cyanur.
2. Add 1:1000 molar ratio of antibody, protein, peptide or ligand to total lipid. This will be equal to 1:5 molar ratio of antibody, protein, peptide or ligand to PEG-Cyanur lipid. For example, in a 2-ml kit, for  $2.2 \times 10^{-7}$  mol of PEG-Cyanur lipid,  $4.4 \times 10^{-8}$  mol of antibody, protein, peptide or ligand is needed.

3. The conjugation must be done under mild basic condition such a borate buffer pH 8.8. Dissolve your antibody, protein, peptide or ligand in borate buffer with pH 8.8
4. Incubate Immunodox®-Cynaur with antibody, protein, peptide or ligand for 16 hours at room temperature.
5. Remove the non-conjugated protein, peptide or antibody from the immunoliposomes by dialysis. We prefer dialysis to size exclusion columns. Dialysis is a much slower process but there will be minimum loss of immunoliposomes after the prep is cleaned from non-conjugated protein/peptide/ligand. Spin columns are much faster; however, you can easily lose over 50% of the liposomes on the spin column. We recommend using [Float-A-Lyzer®](#) dialysis cassette from Spectrum Labs. You will need to choose a cassette with proper MWCO depending on the MW of your protein, peptide, antibody or antibody fragment. **NOTE:** If you decide to use a dialysis cassette, you will need to make sure that the MWCO is below 1,000,000 dalton. At 1,000,000 dalton, the pore size on the dialysis membrane gets close to 100 nm and therefore, your liposomes can be dialyzed out. You cannot use dialysis cassettes and spin columns blindly. They come in various sizes and you need to choose the correct size wisely. Dialyze the immunoliposome solution in 1 liter of PBS at pH 7.4 for 8 hours. Change the dialysis buffer with a fresh 1 liter of PBS and let is dialyze for another 8 hours. After this step, your cleaned up immunoliposome is ready to be used.

## TECHNICAL NOTES

---

- Doxorubicin is a fluorescent molecule with  $\lambda_{ex}$  470 nm and  $\lambda_{em}$  585 nm. If you are using a fluorescent tag on your antibody or ligand, then you need to make sure that they will not interfere with each other.
- Tris buffer should never be used in any step of the process since it contains amine.
- Cyanuric chloride is considered as a sensory respiratory irritant. However, despite the name of the cyanur-modified liposomes, they have not shown any sign of acute, chronic or genotoxicity.



- Cyanur groups are amine-reactive, however, some random attachments of the antibodies can be expected since cyanuric chloride can react with a wide range of nucleophilic functionalities, such as alcohols and thiols. This may interfere with the binding of the antibody to the liposome, and therefore, the binding affinity would change.
- Size exclusion spin columns such as [Sephacrose® CL-4B](#) can be used instead of [Float-A-Lyzer®](#) dialysis cassette. However, a very large amount of liposomes will stick to the column during the cleanup process and therefore we strongly suggest using dialysis than size exclusive beads.
- If you are using a ligand or peptide that is hydrophobic, it is recommended to solubilize it in DMSO or DMF and then add the buffer to it. It is recommended not to use more than 5% volume of DMSO or DMF in the solution. DMF and DMSO are both compatible with liposomes and they are also miscible in water. Other organic solvent such as ethanol and chloroform are not compatible with liposomes and will cause the liposomes to lyse. If you end up using DMSO or DMF then after the conjugation reaction is done, you need to remove DMSO and DMF from the liposomes. In order to do that you need to use a dialysis cassette that is made from REGENERATED CELLULOSE MEMBRANE. **NOTE:** Not all membranes are compatible with DMF and DMSO. We recommend using a [Slide-A-Lyzer™ MINI Dialysis Device](#) with MWCO of 2K made from regenerated cellulose membrane manufactured by ThermoFisher. After DMSO or DMF is removed, you can use [Float-A-Lyzer®](#) dialysis device for the final step of cleaning up the prep.
- Liposomes should be kept at 4 °C and **NEVER** be frozen.

## APPEARANCE

---

Immunodox®-Cyanur is a red translucent liquid made of nano size unilamellar liposomes. Usually due to the small size of liposomes no settling will occur in the bottom of the vial. The liposomes are packaged in an amber vial.

## STORAGE AND SHELF LIFE

---

### Storage

Immunodox® products should always be stored at in the dark at 4 °C, except when brought to room temperature for brief periods prior to animal dosing. DO NOT FREEZE. If the suspension is frozen, the encapsulated drug can be released from the liposomes thus limiting its effectiveness. In addition, the size of the liposomes will also change upon freezing and thawing.

### Shelf Life

Immunodox®-Cyanur is made on daily basis. The batch that is shipped is manufactured on the same day. It is advised to use the products within 4 months of the manufacturing date.

## REFERENCES AND BACKGROUND READING

---

1. [Bendas G, Krause A, Bakowsky U, Vogel J, Rothe U. Targetability of novel immunoliposomes prepared by a new antibody conjugation technique. International journal of pharmaceutics. 1999 Apr 20;181\(1\):79-93.](#)
2. [Lee HY, Mohammed KA, Kaye F, Sharma P, Moudgil BM, Clapp WL, Nasreen N. Targeted delivery of let-7a microRNA encapsulated ephrin-A1 conjugated liposomal nanoparticles inhibit tumor growth in lung cancer. International journal of nanomedicine. 2013;8:4481.](#)
3. [Nyanhongo GS, Steiner W, Gübitz GM, editors. Biofunctionalization of Polymers and their Applications. Springer Science & Business Media; 2011 Aug 6.](#)